Table 2.

Proposed IA2030 Global Strategic Priority Objective Indicators (n = 15) (Detailed in Annex 1 in the Framework for action).

SP 1: Immunization Programmes for PHC/UHC	1.1 Proportion of countries with evidence of adopted mechanism for monitoring, evaluation and action at national and subnational levels	1.2 Density of physicians, nurses and midwives per 10,000 population	1.3 Proportion of countries with on-time reporting from 90% of districts for suspected cases of all priority VPDs included in nationwide surveillance	1.4 Proportion of time with full availability of DTPcv and MCV at service delivery level (mean across countries)	1.6 Proportion of countries with at least 1 documented individual serious AEFI case safety report per million total population
SP 2: Commitment & Demand	2.1 Proportion of countries with legislation in place that is supportive of immunization as a public good		2.2 Proportion of countries that have implemented behavioural or social strategies (i.e., demand generation strategies) to address under-vaccination
SP 3: Coverage & Equity	3.2 DTP3, MCV1, and MCV2 coverage in the 20% of districts with lowest coverage (mean across countries)*
SP 4: Life course & Integration	4.1 Breadth of protection (mean coverage for all WHO-recommended vaccine antigens, by country)
SP 5: Outbreaks & Emergencies	5.1 Proportion of polio, measles, meningococcus, yellow fever, cholera, and Ebola outbreaks** with timely detection and response
SP 6: Supply & Sustainability	6.1 Level of health of the vaccine market, disaggregated by vaccine antigens and country typology**		6.2 Proportion of countries whose domestic government and donor expenditure on primary health care increased or remained stable	6.3 Proportion of countries whose share of national immunization schedule vaccine expenditure funded by domestic government resources increased
SP 7: Research & Innovation	7.1 Proportion of countries with an immunization research agenda		7.2 Progress towards global research and development targets****

Regional and country specific diseases will be considered in regional and country specific frameworks

^***Following attributes will be measured: supply meeting demand; individual supplier risk; buffer capacity; long term competition

^*Will analyze performance in the bottom 20% with national average

^**Includes only outbreaks with an outbreak response vaccination campaign.

^****Targets will be set no later than 2022 and endorsed by SAGE